Navigation Links
Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies
Date:10/4/2011

NEW YORK, Oct. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies
http://www.reportlinker.com/p0284888/Triple-Analysis-Apoptosis-Cancer-Vaccines-and-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis
The apoptosis report part comprises defined and up to date development strategies for 171 apoptotic drugs in oncology (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. This report part extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target strategies, and assesses them in 53 different cancer indications.
This part is based on the following publication:
Apoptotic Therapeutics in Oncology - Where to Commercialize?

Part II: Cancer Vaccines
The cancer vaccine report part comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. This part extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications.
This part is based on the following publication:
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

Part III: Antibodies
The cancer antibody drug report part comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications.
This part is based on the following publication:
The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.



Key Topics Covered:

Part I: Apoptosis
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (146 Drug Targets) 32-276
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? (120 Drug Target Strategies and 171 Drugs) 277-311
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type (7 Different Compound Strategies) 312-355
9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer Indications) 356-440
10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator (125 Investigators) 441-793
12 Drug Index 794
13 Company Index 799
Figures: Includes 6 Figures
Tables: Includes 248 Tables
Total Number of Pages: 803

Part II: Cancer Vaccines
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets) 30-194
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs) 195-308
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 309-338
9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications) 339-386
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators) 387-649
11 Disclaimer 650
12 Drug Index 651
13 Company Index 656
Figures: Includes 6 Figures
Tables: Includes 205 Tables
Total Number of Pages: 659

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (255 Drug Targets) 39-430
7 Emerging New Products to Established Ones: Drug Target Strategies of Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug Targets Strategies and 531 Antibody Drugs) 431-768
8 Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications) 769-893
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531 Antibody Drugs) 894-1,916
10 Disclaimer 1917
11 Drug Index 1918
12 Company Index 1934
Figures: Includes 5 Figures
Tables: Includes 347 Tables
Total Number of Pages: 1,944





To order this report:
Drug and Medication Industry:
Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies
Drug and Medication Business News

More  Market Research Report



Check our  Industry Analysis and Insights


CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Carrot Medical Positioned for Third Straight Year of Triple Digit Growth
2. Reportlinker Adds Triple Analysis: Colorectal Cancer, Lymphoma and Peptides
3. Reportlinker Adds Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer
4. Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies
5. Reportlinker Adds Triple Analysis: Colorectal Cancer, Lymphoma and Pancreatic Cancer
6. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
7. Reportlinker Adds Triple Analysis: Lymphoma, Melanoma and Peptides
8. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides
9. Reportlinker Adds Triple Analysis: Breast Cancer, Leukemia and Cancer Vaccines
10. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
11. Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , February 12, 2016 ... anders vermerkt)   http://www.sedar.com ) ... http://www.telestatherapeutics.com abrufbar.    --> ... Unternehmens http://www.telestatherapeutics.com abrufbar.    ... PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss des zweiten ...
(Date:2/12/2016)... 2016  Sequent Medical, Inc. announced today that it ... the safety and effectiveness of the WEB™ Aneurysm Embolization ... aneurysms.  Prof Laurent Spelle , MD, Head of ... France and Principal Investigator of the CLARYS ... and Germany.  Although patients with ruptured aneurysms ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... When an Au Pair comes all the ... what they are in for and they are often worried things won’t go well. More ... hoping for. This year’s Au Pair of the Year winner’s all commented how their Au ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical Therapy ... Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the country ... in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a ... the integration of Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and ... intelligence (BI) to their small and medium business (SMB) clients. , ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one ... consists of physicians establishing, leading and partnering with ambulatory surgery centers across the United ... Center, also known as an ASC, is a modern health care facility focused on ...
Breaking Medicine News(10 mins):